No Data
No Data
Kura Oncology to Report First Quarter 2025 Financial Results
LifeSci Capital Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $24
H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $40
Strategic Advancements and Early NDA Submission Drive Buy Rating for Kura Oncology
Express News | Kura Oncology Inc: Expects to Receive Notification From FDA on This Preliminary Evaluation in Q2 of 2025
Express News | Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA